Network inference from glycoproteomics data reveals new reactions in the IgG glycosylation pathway by Benedetti, Elisa et al.
ARTICLE
Network inference from glycoproteomics data
reveals new reactions in the IgG glycosylation
pathway
Elisa Benedetti1, Maja Pučić-Baković2, Toma Keser 3, Annika Wahl4,5, Antti Hassinen6, Jeong-Yeh Yang7,
Lin Liu7, Irena Trbojević-Akmačić2, Genadij Razdorov 2, Jerko Štambuk2, Lucija Klarić2,8,9, Ivo Ugrina 3,10,11,
Maurice H.J. Selman12, Manfred Wuhrer 12, Igor Rudan 8, Ozren Polasek13,14, Caroline Hayward 9,
Harald Grallert4,5,15, Konstantin Strauch16,17, Annette Peters5, Thomas Meitinger18, Christian Gieger4,5,
Marija Vilaj2, Geert-Jan Boons7,19, Kelley W. Moremen7, Tatiana Ovchinnikova20, Nicolai Bovin20,
Sakari Kellokumpu6, Fabian J. Theis 1,21, Gordan Lauc2,3 & Jan Krumsiek 1,15
Immunoglobulin G (IgG) is a major effector molecule of the human immune response, and
aberrations in IgG glycosylation are linked to various diseases. However, the molecular
mechanisms underlying protein glycosylation are still poorly understood. We present a data-
driven approach to infer reactions in the IgG glycosylation pathway using large-scale mass-
spectrometry measurements. Gaussian graphical models are used to construct association
networks from four cohorts. We ﬁnd that glycan pairs with high partial correlations represent
enzymatic reactions in the known glycosylation pathway, and then predict new biochemical
reactions using a rule-based approach. Validation is performed using data from a GWAS and
results from three in vitro experiments. We show that one predicted reaction is enzymatically
feasible and that one rejected reaction does not occur in vitro. Moreover, in contrast to
previous knowledge, enzymes involved in our predictions colocalize in the Golgi of two cell
lines, further conﬁrming the in silico predictions.
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Most membrane and secreted proteins are glycosylated,giving the information ﬂow in biological systems anadditional layer of complexity1. Immunoglobulin G
(IgG) is responsible for the majority of antibody-based immunity
in humans and is the most abundant glycoprotein in blood2. Like
all antibodies, soluble IgG is produced and secreted by B lym-
phocytes and has two functional domains: an antigen-binding
fragment (Fab), which is responsible for recognizing antigens on
foreign pathogens and infected cells and a crystallizable fragment
(Fc), which triggers the immune response by interacting with
various Fc receptors3. The Fc domain contains a highly conserved
glycosylation site at asparagine 2974, to which a variety of glycan
structures can be attached. Alternative Fc glycosylation alters the
afﬁnity of IgG to virtually all Fc receptors5,6 and therefore plays
an essential role in mediating the immune response3,7. Further-
more, aberrant glycosylation has been linked to various diseases,
including rheumatoid arthritis8, diabetes9, and cancer10. There-
fore, there is a need to elucidate how IgG glycans are synthesized
and regulated in order to better understand their involvement in
the human antibody-based immune response.
Current knowledge about the protein glycosylation pathway is
likely to be incomplete, as our understanding of the complex
glycan biosynthesis pathway is based solely on in vitro
experiments, which have established the substrate speciﬁcity of
major glycosyltransferase enzymes11. Unfortunately, due to the
complexity of the glycosylation process, the in vivo experimental
validation that is required to account for intracellular localization
and protein-speciﬁc and site-speciﬁc glycosylation is still unfea-
sible, and currently available measurement techniques do not
allow glycosylation to be analyzed at a subcellular level, making it
impossible to experimentally verify whether a given glycosylation
reaction that is enzymatically possible in vitro actually occurs in
the cell. Thus, gaining a more precise picture of protein glyco-
sylation at the molecular level would further our understanding of
how the process is regulated in vivo and possibly identify key
elements that alter glycan proﬁles during pathological processes.
In case of IgG glycosylation, this is expected to guide the devel-
opment of new pharmacological approaches that could replace
cumbersome intravenous immunoglobulin therapy12.
This study attempts to ﬁll part of this knowledge gap using
plasma IgG glycomics liquid chromatography-mass spectrometry
(LC-MS) measurements from four independent cohorts to infer
the enzymatic reactions that are involved in the IgG glycosylation
pathway (Fig. 1). To do this, we ﬁrst generate a partial correlation
network, also known as a Gaussian graphical model (GGM). In
the GGM, the nodes represent individual glycans and the edges
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Fig. 1 Analytical procedure. Starting from the IgG glycan abundances measured using LC-ESI-MS (1), we calculated a correlation-based network (2) and
mapped it to the known IgG glycosylation pathway (3). We found that most edges in the network corresponded to single enzymatic steps in the pathway
(4). Based on this ﬁnding, we inferred unknown enzymatic reactions that were putatively involved in the synthesis of IgG glycans using a rule-based
approach (5). We then replicated the ﬁndings using four cohorts (6) and performed different in vitro validation experiments to conﬁrm the predicted
reactions (7)
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represent their pairwise correlations, corrected for the con-
founding effects of all other glycans and clinical covariates.
Previous studies using serum metabolomics data have shown that
highly correlated pairs in GGMs represent enzymatic reac-
tions13,14. This is the ﬁrst study to apply GGMs to large-scale IgG
glycomics data from four independent populations. We ﬁnd that
signiﬁcant partial correlations predominantly occur between
glycan structures that are one enzymatic step apart in the known
IgG glycosylation pathway shown in Fig. 2, demonstrating that
network statistics on quantitative glycoprotein measurements
allow us to detect true enzymatic reaction steps in the glycosy-
lation pathway.
Based on this result, we expect edges in the GGM that did not
appear in the known pathway to represent true but hitherto
unknown enzymatic steps, i.e., unknown substrate speciﬁcities of
the enzymes in the pathway. To investigate this hypothesis, we
develop a rule-based inference approach to test alternative
pathway models. This shows that additional reactions are sup-
ported by the data for all four cohorts. More in detail, we predict
that bisection of fucosylated, galactosylated glycans, as well as
galactosylation of monosialylated glycans occur during IgG gly-
can synthesis. As direct experimental validation is considered
unfeasible for the reasons outlined above, we validate our ﬁndings
with two different approaches. First, we use a genome-wide
association study (GWAS) in a ﬁfth cohort. It has previously been
shown that the substrate–product ratios of metabolites are asso-
ciated with their enzymes in GWAS15,16. Therefore, we consider
the ratios of substrate–product pairs of the predicted reactions as
quantitative traits, with which we can conﬁrm several of our
predicted reactions across the IgG subclasses. Second, we perform
three sets of in vitro experiments to conﬁrm the predicted
enzymes substrate speciﬁcities, as well as their colocalization
inside the Golgi apparatus. Our results show that at least one of
the inferred reactions occurs in vitro, that one rejected rejection
does not occur, and that the glycosyltransferases involved in the
predicted reactions are colocalized in the Golgi stacks of two
different cell lines.
Results
IgG glycomics correlation networks. We measured the abun-
dances of plasma IgG Fc N-glycopeptides in four Croatian
cohorts—two from the island of Korčula (one sampled in 2010
and one in 2013), one from the island of Vis, and one from the
city of Split (Table 1)—using liquid chromatography coupled with
electrospray mass spectrometry (LC-ESI-MS). For each indivi-
dual, we detected the abundances of 50 glycoforms—20 for IgG1,
20 for IgG2 and IgG3 combined (hereafter referred to as IgG2),
and 10 for IgG4 (see Methods). In total, 20 different glycan
structures were measured. Non-fucosylated glycans were not
quantiﬁed for IgG4 due to their low abundances.
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Fig. 2 IgG glycan structures and the known glycosylation pathway. IgG glycans are biantennary complex-type structures: all measured glycoforms
have a common core structure (the G0 structure, top left) to which additional sugars can be attached. The glycan names describe how many galactoses
(G0/G1/G2) are present, whether there is a core fucose (F) or a bisecting N-acetylglucosamine (also referred to as GlcNAc, N), and whether the structure
includes one or two sialic acids (S1/S2). The known glycosylation pathway as described in the review of Taniguchi58 is shown, with boxes representing
glycan structures and arrows representing single enzymatic reactions in the synthesis process. Each enzymatic reaction involves the addition of a single
sugar unit to the glycan structure. The 20 glycoforms measured in this study are produced by four enzymes (FUT8, B4GalT1, MGAT3, and ST6Gal1). The
gray boxes represent IgG glycoforms that were not measured in the present study. For a list of the primary literature describing the in vitro experiments
which the pathway is based on, see Supplementary Fig. 1
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The Korčula 2013 cohort was selected for use in the discovery
analysis. The results for all other cohorts are discussed in the
replication section below. Glycan measurements were obtained
for 695 individuals (277 men and 418 women) in the discovery
cohort. Following preprocessing, which included data normal-
ization and the removal of missing values and related individuals
from the data set (see Methods), 669 samples (271 men and 398
women) remained, with an age range of 18–88 years.
We used both regular Pearson correlation and partial
correlation analysis to make comparisons. The partial correlation
analysis tested the conditional dependency between two variables
when accounting for the confounding effects of all other glycans,
as well as age and gender. In total, 905 Pearson correlation
coefﬁcients were signiﬁcantly different from zero following
multiple testing correction (false discovery rate (FDR)= 0.01).
This signiﬁcance level corresponded to an absolute correlation
cutoff of 0.105, with coefﬁcients approximately symmetrically
distributed around zero (Supplementary Fig. 2A). Partial
correlation coefﬁcients are, by nature, much lower in absolute
value than Pearson coefﬁcients, and so only 66 of the total 1275
coefﬁcients were found to be signiﬁcant, the majority of which
were positive (Supplementary Fig. 2B).
Upon inspection of the correlation matrices, we observed a
remarkably similar structure between the different IgG subclasses
(Supplementary Fig. 2C, D)—that is, glycoforms that were
strongly correlated in one subclass also tended to be strongly
correlated in the other subclasses. Moreover, there were only a
few signiﬁcant correlation coefﬁcients for cross-subclass glycan
pairs (off-diagonal blocks of the matrix). This suggests that the
regulation of IgG is highly conserved across subclasses. Interest-
ingly, seven of the nine cross-subclass pairs involved glycans with
the same structure. For a full list of the partial correlations, see
Supplementary Data 1.
The Pearson and partial correlation matrices were represented
as networks (i.e., weighted graphs), with the nodes representing
glycans and the edges indicating statistically signiﬁcant coefﬁ-
cients (Fig. 3a, b). Most of the network edges connected glycan
pairs that differed by only a single monosaccharide residue. This
directly reﬂects the underlying glycan synthesis pathway, whereby
monosaccharides are added one at a time and in a given order to
create the ﬁnal glycoform (Fig. 2). Furthermore, unlike the GGM,
which showed a strong modularity with respect to the IgG
subclasses, the Pearson correlation network did not show a clear
separation between the subclasses (Fig. 3c, d). This indicates that
signiﬁcant partial correlations were mostly found between glycans
belonging to the same IgG subclass, with few signiﬁcant
correlations between glycans with different IgG isoforms. To
investigate this observation quantitatively, we calculated a
subclass-based network modularity for all signiﬁcantly positive
edges based on the method by Newman34, and as previously
adapted by Krumsiek13. We used degree-preserving random edge
rewiring as a null model to assess the statistical signiﬁcance (see
Methods). The computed modularity for the original network was
Q= 0.495 with an empirical P-value of <10−5, proving a high
level of subclass-speciﬁc modularity.
Overlap of GGM with known IgG glycosylation pathway. We
systematically investigated the relationship between the known
IgG glycosylation pathway (Fig. 2) and the data-driven GGM
(Fig. 3b). To do this, we deﬁned the “pathway distance” between
any pair of glycans as the minimum number of enzymatic steps
separating the two structures—for example, two glycans that
corresponded to the reactant and product of a single enzymatic
reaction in the IgG glycosylation pathway had a pathway distance
of 1, whereas the shortest path from G0 to G2S1 includes three
enzymatic steps, giving them a pathway distance of 3. We could
not interpret correlations between glycans with the same struc-
ture belonging to different IgG subclasses in terms of the enzy-
matic reactions because they are bound to different proteins, and
so we labeled these “X” (Fig. 4). All other cross-subclass glycan
pairs were ignored in our analysis.
Signiﬁcant Pearson correlation coefﬁcients were found for both
short and longer pathway distances (Fig. 4a); however, there were
far more signiﬁcant partial correlation coefﬁcients at a pathway
distance of 1 (Fig. 4b) than at any other pathway distance,
demonstrating that signiﬁcant partial correlations tend to occur
between glycans that are directly connected in the pathway. To
assess whether signiﬁcant partial correlations occurred more
often at a given pathway distance than expected by chance, we
performed a Fisher’s exact test. The results of the test were highly
signiﬁcant (P= 3.41 × 10−39; Fig. 4c, d), proving that there is a
strong relationship between the data-driven GGM and the known
IgG glycosylation pathway.
Rule-based prediction of new enzymatic reactions. Above, we
demonstrated that signiﬁcant partial correlation coefﬁcients
represent pairs of glycans that are directly linked in the known
IgG glycosylation pathway. Interestingly, however, there were also
22 signiﬁcant partial correlations for pathway distances greater
than 1 (and not contained in the “X” group), as indicated by the
black oval in Fig. 4b. Therefore, given the strong evidence for a
relationship between the GGM and the IgG glycosylation path-
way, we hypothesized that these correlations represented true but
yet unknown pathway reactions. In principle, all glycans that
differ in structure by a single monosaccharide could be connected
Table 1 Characteristics of the four cohorts analyzed
Korčula 2013
discovery
Korčula 2010
replication
Split replication Vis replication KORA validation
Number of measured
glycans
50 50 50 50 50
IgG1 IgG2 IgG4 20 20 10 20 20 10 20 20 10 20 20 10 20 20 10
Total number of samples 695 951 994 780 1823
Males Females 277 418 339 612 390 604 326 454 888 935
Samples with no missing
values
669 849 980 729 1641
Unrelated samples 669 504 980 395 1641
Males Females 271 398 156 348 386 594 152 243 793 848
Age range 18–88 18–90 18–85 18–91 32–81
(median,IQR) (52,24) (56,18) (52,21) (54,24) (61,14)
(mean,std) (53,16) (56,14) (50,14) (55,15) (61,9)
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by a reaction performed by one of the four enzymes involved in
the glycosylation pathway shown in Fig. 2; and among these
22 signiﬁcant correlations, 15 (68%) differed by only one sugar
residue. Furthermore, if we discard the seven negative partial
correlations, whose interpretation has been shown to be proble-
matic13, this increases to 88% (Supplementary Data 1). Thus, all
15 of these glycan pairs are candidates for direct enzymatic
reactions.
To analyze this quantitatively, we tested whether these
unexplained partial correlations could be attributed to missing
steps in the known pathway. To do this, we ﬁrst created a list of
all possible novel pathway reactions, i.e., all connections between
glycan structures that only differed by a single sugar unit and that
were not present in the known IgG glycosylation pathway. Since
we followed an unbiased approach, this included reactions for
which in vitro experiments showed evidence of inhibition, e.g.,
the addition of fucose to the G0N structure17. We then divided
these initial reactions into sets of “rules” according to the features
of the hypothetical substrate and the corresponding enzyme
performing the reaction (Fig. 5a and Table 2)—i.e., we built the
rules to account for previously undescribed substrate speciﬁcities
for the four glycosyltransferases involved in IgG glycosylation.
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Fig. 3 Network representation and modularity. a, b Pearson and partial correlation matrices, respectively, visualized as networks, where the nodes
represent different glycoforms, and the edges indicate signiﬁcant positive (black) and negative (red) correlations. Different node shapes correspond to
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For example, the ﬁrst rule (F1) describes the fucosylation of
galactosylated, non-bisected glycans, as these reactions are not
included in the known pathway. In this way, starting from
22 single potential new reactions, we deﬁned six rules, as
described in Fig. 5a and Table 2.
The rationale for our inference method and model selection
technique was that the pathway model that contains the greatest
proportion of true reactions should produce the lowest P-value
with a Fisher’s exact test, as seen in Fig. 4c. In total, we considered
63 pathway models that extended the known glycosylation
pathway using all combinations of the six rules described above.
To obtain a robust model ﬁt, we performed bootstrapping with
10,000 resamplings and calculated 95% conﬁdence intervals for
each P-value distribution. We considered a pathway model to ﬁt
the data signiﬁcantly better than the known pathway if it had a
lower Fisher’s test P-value and its 95% conﬁdence interval did not
overlap with that of the known pathway. Where several proposed
pathway models were found to perform signiﬁcantly better than
the known pathway, we chose the simpler model, i.e., the one that
included the fewest rules. Note that for this analysis we used P-
values as variance-normalized measures of effect size for model
comparison, rather than as the probability of an event occurring
by chance. Figure 5b shows a comparison of the P-values for the
known pathway, the known pathway extended with any one of
the six deﬁned rules, and all combinations that gave a
signiﬁcantly better P-value than the known pathway alone. A
list with the results for all 64 (26) pathway models, including the
known pathway for reference, can be found in Supplementary
Data 2.
In the selected pathway model from this analysis, rules G1 and
N2 were added to the known pathway (Fig. 5c), which resulted in
the inclusion of eight new enzymatic steps in the IgG
glycosylation pathway. By considering this selected model as
the ground truth and reclassifying all partial correlations
according to the pathway distances derived from this extended
model, we found that most of the signiﬁcant partial correlations
that had longer distances in the original IgG glycosylation
pathway (Fig. 4b) had a pathway distance of 1 in the modiﬁed
IgG glycosylation pathway (Fig. 5d). Note that the pathway model
that included all possible enzymatic reactions (model
“F1F2F3G1N1N2” in Fig. 5b) did not yield the lowest P-value,
indicating that the addition of more reactions than required to
provide the optimal pathway model impaired the result.
Replication in three additional cohorts. We replicated these
ﬁndings using IgG glycomics data measured on the same plat-
form in three independent Croatian cohorts (Table 1). We again
observed that most partial correlation coefﬁcients between gly-
cans were positive (Supplementary Fig. 3) and that the calculated
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25th and 75th percentiles, respectively. The label “X” represents correlations between the same glycoforms across different IgG subclasses. In line with the
network visualization, we observed signiﬁcant Pearson correlation coefﬁcients across all pathway distances, suggesting that Pearson correlations are non-
speciﬁc with respect to the IgG glycosylation pathway. By contrast, signiﬁcant partial correlation coefﬁcients accumulated at a pathway distance of 1. The
black dashed oval highlights signiﬁcant partial correlations for pathway distances >1. c P-values for Fisher’s exact tests for both Pearson and partial
correlations at different pathway distances. There were signiﬁcantly more signiﬁcant partial correlations between glycans with a pathway distance of 1,
demonstrating a close relationship between the IgG glycosylation pathway and the reconstructed GGM. The log10 P-values can be interpreted as a
variance-normalized measure of the effect size. d Contingency table for the partial correlations at a pathway distance of 1. Entries represent the numbers of
partial correlations satisfying the corresponding conditions
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GGM displayed a highly modular structure with respect to the
IgG subclasses (Supplementary Fig. 4). Moreover, pathway ana-
lysis showed that the edges represented single enzymatic steps in
the IgG glycosylation pathway in all GGM networks (Supple-
mentary Fig. 5). When inferring possible additional enzymatic
steps, we again found that the addition of rules G1 and N2 to the
known pathway gave a signiﬁcantly better overlap with the GGM
(Supplementary Fig. 6), providing further evidence that the
enzymatic reactions included in these rules represent true steps in
the IgG glycosylation pathway. The GGMs for all cohorts can be
found in Supplementary Software.
To quantitatively evaluate the agreement between GGMs
across the four cohorts, we generated a consensus network that
represented the overlap between the networks (Fig. 6a). We
considered an edge to be “replicated” if it was signiﬁcant in all
four cohorts. This showed that 44 of the 140 signiﬁcant
correlations were replicated across all four cohorts (Fig. 6b). To
investigate how these edges related to the IgG glycosylation
pathway, we again performed a Fisher’s exact test. We only
considered partial correlations that were found to be signiﬁcant in
at least one cohort, and built a contingency table that classiﬁed
these according to their replication status and pathway distance
(Fig. 6c). The highly signiﬁcant result of this test (P= 7.73 ×
10−12) indicates that the replicated edges tend to represent true
pathway reactions even more strongly than the non-replicated
edges do, demonstrating that partial correlations corresponding
to single enzymatic reactions in the IgG glycosylation pathway
were robustly identiﬁed in all cohorts.
GWAS evidence for predicted reactions. We applied a GWAS-
based approach on an independent cohort to provide evidence-
based validation, assuming that signiﬁcant associations between
glycan ratios and single-nucleotide polymorphisms (SNPs) in the
IgG glycosyltransferase genes indicate that the underlying reac-
tions truly exist. This rationale is based on previous studies on
blood metabolomics data, in which ratios of two metabolites were
frequently found to be associated with genetic variation in the
gene region of their catalyzing enzymes (see, e.g., Gieger15;
Suhre16; Shin14). To quantify the increase of association strength
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Fig. 5 Rule-based approach for pathway inference. a Sketch of all single-monosaccharide additions in the IgG glycosylation pathway. The black network
represents the known IgG glycosylation pathway, while arrows with the same color describe a rule. Shades of the same color represent reactions performed
by the same enzyme. b Fisher’s exact test results for the addition of different combinations of rules to the known pathway. The pathway model that most
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signiﬁcantly more accurate than the known pathway is indicated by a black arrow and includes rules G1 and N2. For a full list of results, see Supplementary
Data 2. c Pathway model inferred by our approach. d Partial correlation coefﬁcients for different pathway distances in the selected model. On each box, the
central mark indicates the median, and the whiskers indicate the 25th and 75th percentiles, respectively. Most of the signiﬁcant partial correlations that
were a long distance apart in the known pathway are now at a distance of 1 (cf. Fig. 4b)
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of the ratio with respect to the single glycans, p-gains as deﬁned in
ref. 18 were used. Only signiﬁcantly associated ratios with a suf-
ﬁcient p-gain (see Methods) were considered to conﬁrm a given
enzymatic reaction.
For this analysis, we used glycomics data from the German
population study KORA F419. Plasma IgG Fc N-glycopeptide
measurements were obtained using the same LC-ESI-MS
platform as for the discovery and replication cohorts described
above, and included the same 50 measured glycoforms. Linear
associations with genetic variants were calculated using the
logarithm of all glycan product–substrate ratios deﬁned in Fig. 5a
(see Methods).
We considered SNPs in the four glycosyltransferase genes
involved in IgG glycosylation (ST6GAL1, B4GALT1, FUT8, and
MGAT3, see Supplementary Table 1). As a positive control, we
ﬁrst veriﬁed that the glycan product–substrate ratios in the
known pathway were signiﬁcantly associated with loci in the
regions coding for the enzymes that are catalyzing the reactions.
We found that 12 out of 47 ratios were genome-wide signiﬁcant,
while another ﬁve met a suggestive P-value of 10−7 (Fig. 7, thick
black lines). Interestingly, we also found one ratio (G2/G1 in
IgG2) that was associated with genetic variants in the region of
the enzyme FUT8, which is responsible for the addition of core
fucose (Fig. 7, arrow with asterisks). This was unexpected as
neither of the structures in the ratio are fucosylated.
For our 22 predicted reactions, we found three signiﬁcant and
three suggestive hits (Fig. 7, thick green lines). Importantly, these
signiﬁcantly associated ratios tended to be the same across the
three IgG subclasses and were equally distributed across the
predicted rules. We found three conﬁrmations for the rule G1 and
three for the rule N2. By contrast, ﬁve signiﬁcant associations and
one suggestive hit were observed among the 26 ratios that were
not predicted by our approach, but these did not replicate across
subclasses (Fig. 7, thick gray lines). In particular, three out of
these six non-predicted reactions originated from rule F1
exclusively in IgG1 and could not be replicated in IgG2, while
the other three hits spread across three different rules.
Overall, we found at least one genome-wide signiﬁcant
association for all of the considered genes, providing evidence
that we could indeed investigate all four glycosyltransferase
enzymes involved in IgG glycosylation. The complete GWAS
results can be found in Supplementary Data 3, while the regional
association plots for visual inspection are provided in Supple-
mentary Fig. 7.
Experimental validation by enzymatic assays. To address dif-
ferent aspects of our predictions, we performed three sets of
in vitro experiments: two enzymatic assays and one colocalization
experiment.
In a ﬁrst experiment, we aimed to verify whether GalT1 and
MGAT3 exhibited the predicted, previously unknown substrate
speciﬁcities. To this end, we compared ultra performance liquid
chromatography (UPLC) spectra of pooled IgG glycans before
and after exposure to the two enzymes (see Methods). We
considered seven different experimental conditions, covering
various combinations of enzyme concentrations as well as
negative controls (lacking sugar donors) that are not expected
to show any reaction (Fig. 8a). As expected, GalT1 efﬁciently
galactosylated a number of glycans in the IgG glycome (see
Supplementary Data 4). To investigate our inferred reactions, we
focused on the ratio of the substrate G1FS1 and product G2FS1.
With increasing concentrations of added GalT1 enzyme (25, 50,
and 100 ng), this ratio drops signiﬁcantly compared to the
respective negative controls (Fig. 8a), directly conﬁrming one of
the predicted reactions in rule G1 in a concentration-dependent
manner. When performing the analogous experiment for
MGAT3, however, we were not able to see addition of the
bisecting GlcNAc to any of the glycans (not even reactions in the
known IgG glycosylation pathway) (Supplementary Data 4). This
might indicate that the ﬂuorescent label attached to the IgG
glycans interferes with the enzymatic reaction. For this reason, we
were not able to experimentally prove or disprove any enzymatic
reaction in rule N2.
Table 2 Rules for pathway inference
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In a second experiment, we focused on a reaction from an
excluded rule, namely the addition of bisecting GlcNAc to
galactosylated non-fucosylated glycans (rule N1). To this end, we
performed the enzymatic reaction with a pure G2 synthetic
glycopeptide (see Supplemental Methods). For positive control,
we also considered a G0 glycopeptide, a known substrate for
MGAT3. While the G0 structure was completely converted to
product within 3 h (Supplementary Fig. 8A), there was no
measurable addition of bisecting GlcNAc to the G2 structure even
after 48 h (Supplementary Fig. 8B). The latter result was further
conﬁrmed using a ﬂuorescently labeled G2 glycan structure,
which also did not show any conversion to G2N (Supplementary
Fig. 8C). These experiments are thus supportive of our prediction
that rule N1 is not enzymatically feasible.
Enzyme colocalization experiments in cell lines. In vitro evi-
dence for enzymatic reactions does not necessarily translate to
in vivo conditions. A general consensus in the ﬁeld has been that
Golgi glycosyltransferases mainly localize in the stack of cisternae
according to their expected order of functioning20,21. In parti-
cular, this is expected to prohibit the bisection of galactosylated
glycans due to the different localization of the enzymes. In con-
trast, our predictions suggest that the addition of bisecting
GlcNAc can occur also on galactosylated, fucosylated glycans
(rule N2).
To address this aspect, we performed colocalization experi-
ments of the enzymes involved in our predicted reactions, namely
B4GalT1, MGAT3, and ST6Gal1, in kidney COS-7 cells and
CaCo-2 colorectal cancer cells. Evidence of such a colocalization
between the three glycosyltransferases would indicate that our
predictions are, in fact, not impossible. Localization of the
enzymes in the Golgi stacks of cisternae (cis-, -medial, -trans) was
assessed using confocal microscopy and Z-stack imaging with
Venus-tagged or Cherry-tagged enzyme constructs expressed at
modest levels both in COS-7 and CaCo-2 cells. The latter have the
advantage of having Golgi stacks dispersed throughout the
cytoplasm, facilitating colocalization analyses at the level of
individual Golgi stacks, and thereby aiding interpretation of the
imaging data. In addition, cells were stained with anti-GM130 cis-
Golgi marker antibody.
The overlap between the enzymes and GM130 was on
average 62%/73% (MGAT3), 55%/67% (B4GalT1), and 51%/
67% (ST6Gal1) in CaCo-2/COS-7 cells, respectively (Supple-
mentary Fig. 9). This means that, to different degrees, all three
enzymes can be found in the cis-part of the Golgi. Higher
overlap percentages were detected in COS-7 cells due to the
more compact Golgi architecture in the cells. Comparing the
overall localization of the three enzymes, we observed
prominent colocalization. The overlaps were quantiﬁed as
69%/65% (B4GalT1-MGAT3), 76%/71% (B4GalT1-ST6Gal1),
and 68%/66% (MGAT3-ST6Gal1) in CaCo-2/COS-7 cells,
respectively (Fig. 8b, c). These data indicate that, unexpectedly,
a substantial proportion of all these three enzymes are present
in the same Golgi compartments, indicating that our newly
proposed reactions described by rules G1 and N2 are
compatible with enzyme localization inside the Golgi stacks
of cisternae.
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Fig. 6 Replication. a Consensus network. Black edges represent replicated partial correlations that correspond to direct enzymatic steps in the known IgG
glycosylation pathway, green edges represent replicated edges matching the reactions predicted by our approach, and red edges represent replicated
correlations corresponding to reactions that were not predicted to take part in IgG glycosylation. Replicated edges were deﬁned as partial correlations that
were signiﬁcant in all four cohorts. Gray edges represent partial correlations that were signiﬁcant in at least one cohort but not in all four. Note that three of
the ﬁve replicated but non-predicted edges linked the same glycan structure in different IgG subclasses, which we did not consider in our inference
approach. Thus, there are only two edges that are truly non-predicted. b Venn diagram of the signiﬁcant partial correlations in the four cohorts. In total,
44 edges were shared among all four cohorts. c Contingency table for the partial correlation coefﬁcients that were found to be signiﬁcant in at least one of
the four considered cohorts. The classiﬁcation variables in this case are replication status and pathway distance. Here, we considered edges that were
signiﬁcant in at least one of the four cohorts, and we considered an edge to be replicated if it occurred in all four cohorts. The resulting P-value was very
low, indicating that replicated edges are more likely to represent enzymatic reactions than non-replicated edges
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Discussion
In this study, we demonstrated for the ﬁrst time that GGMs can
be used to reconstruct single enzymatic reaction steps in the
glycan synthesis pathway using IgG Fc glycan measurements
from human plasma. We also found that additional glycosylation
reactions can be inferred from the calculated network, with the
pathway rules G1 and N2 (Table 2) likely representing real bio-
chemical steps in the IgG glycosylation pathway.
Rule G1 represents the galactosylation of sialylated glycans.
The current standard glycosylation pathway is based on immu-
nohistochemical studies that were performed over 30 years ago,
which suggested different subcellular localization of galactosyl-
transferases and sialyltransferases in the Golgi apparatus22,23.
Galactosylation is a pre-requisite for sialylation, and so the
hypothesis of physically separated enzymes implied that galac-
tosylation could only occur prior to sialylation. However, it has
recently been shown that these two enzymes are colocalized in
COS7 cells and are likely to act as a complex24. Our results
directly support this hypothesis, as rule G1 represents sialylation
of IgG prior to further galactosylation.
Rule N2 suggests that fucosylated, galactosylated glycans can be
modiﬁed by adding a bisecting GlcNAc through MGAT3. Again,
the standard glycosylation pathway assumes differential locali-
zation of the B4GalT1 and MGAT3 enzymes, and thus that the
addition of bisecting GlcNAc could only occur prior to galacto-
sylation. Previous studies have moreover indicated that over-
expression of the B4GalT1 enzyme decreases the amount of
bisecting GlcNAc (Fukuta et al. 2000), suggesting that the two
enzymes might mutually inhibit each other’s activity by com-
peting for the same substrate. In contrast, our results suggest that
the two enzymes may be colocalized and that galactosylated
glycans could be direct substrates for MGAT3, hinting at a dif-
ferent regulation of the enzymatic activity than previously
described.
As a limitation, it is to be noted that partial correlations cal-
culated from glycomics data might not represent true biological
processes in all cases. For example, we observed cross IgG-
subclass correlations of the same glycan structures, which might
be attributed to overall sugar or glycan abundances, rather than
single enzymatic steps. Vice versa, not all glycan pairs that share a
biochemical reaction will necessarily show correlation in the data.
Reasons for this could be too low concentrations of glycans or
high turnover rates of the IgG antibodies in blood. However, we
used the correlation-based methodology to generate novel path-
way hypothesis for experimental testing, which does not require a
perfect reconstruction of the pathway.
Our ﬁndings were replicated across the analyzed cohorts,
suggesting that the mechanisms that regulate IgG glycosylation
are conserved across different Croatian populations. To validate
our hypothesis for new enzymatic reactions in the IgG glycan
synthesis pathway, we performed GWAS on glycan
product–substrate ratios. Previous GWAS analyses on total IgG
glycans measured with UPLC in the Vis and Korčula 2010
cohorts revealed statistically signiﬁcant associations between
traits describing fucosylated, non-bisected glycans, and the
MGAT3 gene9. Here, we used speciﬁc glycan product–substrate
ratios as quantitative traits, allowing us to analyze individual
reactions at an IgG subclass-speciﬁc level. Six ratios that corre-
sponded to our predicted reactions were found to be signiﬁcantly
associated with SNPs in the gene regions coding for the enzymes
involved in the putative reactions (three for rule G1 and three for
rule N2, see Supplementary Data 3), further supporting our
hypothesis of these novel pathway steps occurring in vivo.
The GWAS evidence stems from an in vivo system; however, it
is an indirect association and does not provide proof for the
predicted reactions. Therefore, we performed in vitro enzyme
assays probing speciﬁc reactions from the inferred pathway
model. We found evidence that the addition of galactose to
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Fig. 7 GWAS results for glycan ratios. a Reference pathway for interpreting the GWAS results. Black lines represent reactions in the known IgG
glycosylation pathway, green lines represent reactions associated with the predicted rules, and gray lines represent possible reactions that were not
selected by our approach. b–d GWAS results for IgG1, IgG2, and IgG4, respectively. Solid thick arrows represent ratios that were signiﬁcantly associated
with SNPs in the regions coding for an IgG glycosylation enzyme (P< 5.26 × 10−10 and p-gain> 10). Dashed arrows represent suggestive associations
(5.26 × 10−10≤ P≤ 10−7 and p-gain> 10). Gray nodes in the IgG4 plot represent glycoforms that were not measured. The asterisk indicates that the ratio
was unexpectedly associated with SNPs in the FUT8 gene region
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monosialyated glycans via B4GalT1 is indeed possible (rule G1).
Conﬁrming or disproving reactions in rule N2 was not possible
due to experimental limitations. Moreover, we were able to show
that a reaction from the rejected rule N1 did indeed not occur in
the experiment. In addition to substrate speciﬁcity, current
knowledge of the physical distribution of enzymes across the
Golgi apparatus implied a directed order of the enzymes involved
in the glycosylation process, thus preventing our predicted reac-
tions from occurring in cells. In contrast to this, we found that the
three enzymes involved in our predictions (B4GalT1, MGAT3,
ST6Gal1) strongly colocalize across the Golgi in two different cell
lines, suggesting that, in fact, the reactions are not unfeasible.
Taken together, while full in vivo validation of the new reactions
is out of reach at this point, we found substantial evidence sup-
porting our prediction in in vitro experiments.
Future studies could build on our ﬁndings in several ways. (1)
The predicted rules could be investigated at a single-reaction level
to determine whether all or only some of the enzymatic steps
described in rules G1 and N2 are included in the IgG glycan
synthesis pathway. (2) In addition, a single-reaction pathway
inference approach could be used to explore the subclass-speciﬁc
pathways suggested by some of our GWAS results. (3) The
approach described in this paper could also be used to analyze
other glycomics data sets, obtained from different platforms (e.g.,
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Fig. 8 Experimental validation results. a In vitro enzymatic assay. The ﬁgure illustrates the ratio of G1FS1 over G2FS1 across different concentrations of the
enzyme (B4GalT1), and in presence or absence of sugar donors. Bars represent the average value over triplicates, while error bars represent standard
deviations. With increasing enzyme concentrations, the glycan ratio decreases signiﬁcantly with respect to the corresponding negative control, conﬁrming
the occurrence of the predicted reaction. P-values were obtained from a two sample t-test. b Quantitative overlap between the localization of the three
enzymes. The overall colocalization of each enzyme pair is expressed as an overlap coefﬁcient percentage (mean %± standard deviation). We observe
substantial colocalization of all enzyme pairs in both cell lines. c Exemplary colocalization images of B4GalT1, ST6Gal-1, and MGAT3 in CaCo-2 (left) and
COS-7 (right) cells, used for the overlap quantiﬁcation in b. The individual ﬁgures represent a typical view from ﬁve different Golgi areas examined. In the
images labeled as “Merged” and “Zoom”, yellow areas represent enzymatic overlap. Due to the dispersed Golgi stacks throughout the cytoplasm in Caco-2
cells, the overlap can be observed clearly in separated cisternae, proving that localization of the glycosyltransferases is not limited to cis-Golgi, medial-
Golgi, or trans-Golgi areas. Bar represents 5 μm
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UPLC ﬂuorescence [FLR], matrix-assisted laser desorption ioni-
zation—time-of-ﬂight—MS [MALDI-TOF-MS], or multiplexed
capillary gel electrophoresis with laser-induced ﬂuorescence
detection [xCGE-LIF]; Huffman) to investigate whether the same
reconstructed pathways are produced. (4) Measurement techni-
ques for total plasma glycomes, including glycoforms with
extremely heterogeneous structures (i.e., high mannose, hybrid,
truncated, and complex glycans) from approximately 24 glyco-
proteins in blood, have recently become available25. Therefore, it
would be of major interest to apply our methodology to these
more complex data sets, to determine whether partial correlations
can be used to reconstruct single enzymatic reactions even when
dealing with a heterogeneous set of glycoproteins. (5) Replication
of the results should also be veriﬁed in a non-Croatian cohort, as
population-speciﬁc effects may have gone undetected in this
analysis. (6) From a theoretical perspective, an analytical for-
mulation of the likelihood function of the different pathway
models based on information criteria such as the AIC (Akaike) or
BIC (Bayesian) would lead to more rigorous model selection.
In conclusion, in this study we demonstrated for the ﬁrst time
that GGMs based on large IgG glycomics data sets contain strong
footprints of biochemical reactions in the IgG glycosylation
pathway. We proposed an inference algorithm based on the
accordance of GGMs and the candidate pathways, to improve our
understanding of the complex process of protein glycosylation.
Novel reaction steps could be partially validated using GWAS
data and in vitro experiments. In general, the ﬁnding that GGMs
can be used to represent single steps in glycan synthesis indicates
that it may be possible to compare the GGMs from healthy and
sick individuals to detect alterations in enzymatic activity of the
glycosyltransferases, shedding light on the molecular mechanisms
that regulate IgG glycosylation.
Methods
Study populations. In this study, plasma samples were obtained from ﬁve cohorts.
Samples for the discovery and replication analyses came from the Croatian islands
of Vis and Korčula, and were obtained from the “10001 Dalmatians” biobank10,
while samples for a second cohort from Korčula and a cohort from Split were
collected separately a few years later (see Table 1 for details). For the purposes of
the analysis described in this paper, we only considered unrelated individuals and
samples with no missing values. Kinship coefﬁcients26 were estimated based on
identity-by-state, which were computed using genotyped SNP data with the IBS
function in the GenABEL package27 for R. Unrelated individuals were obtained by
selecting all pairs of individuals whose kinship coefﬁcient was higher than 0.0312,
which removed all individuals that were ﬁrst-degree cousins or closer.
Validation was performed using the German study population KORA
(“Kooperative Gesundheitsforschung in der Region Augsburg”; Wichmann19),
which includes 3788 DNA samples with 18,185,628 SNPs (after QC) and 1887
glycomics samples. 1823 samples included both gene information and glycan
concentrations and were considered in the analysis (Table 1).
All participants to the KORA study are residents of German nationality
identiﬁed through the registration ofﬁce and written informed consent was
obtained from each participant. The study was approved by the local ethics
committee (Bayerische Landesärztekammer). The Croatian cohorts received ethical
approval of the ethics committee of the University of Split School of Medicine, as
well as the South East Scotland Research. Written informed consent was obtained
from each participant.
Glycoproteomic measurements. IgG was isolated from the plasma using afﬁnity
chromatography with 96-well protein G monolithic plates, as reported in
the Supplementary Methods. IgG Fc glycopeptides were extracted through trypsin
digestion and measured by LC-ESI-MS, which allows the separation of different
IgG isoforms of glycans. In Caucasian populations, the tryptic Fc glycopeptides of
IgG2 and IgG3 have identical peptide moieties28,29 and so are not distinguishable
using the proﬁling method. Furthermore, only 10 glycoforms of IgG4 were
detectable due to the low abundance of this IgG subclass in human plasma. A
detailed description of the experimental procedure can be found in the Supple-
mentary Methods.
Data preprocessing. For each IgG subclass, the LC-ESI-MS raw ion counts were
normalized using probabilistic quotient normalization, which was originally
introduced for metabolomics measurements30. The reference sample was
calculated as the median value of each glycan abundance across all measured
samples. For each sample, a vector of quotients was then obtained by dividing each
glycan measure by the corresponding value in the reference sample. The median of
these quotients was then used as the sample’s dilution factor, and the original
sample values were subsequently divided by that value. This procedure was repe-
ated for each sample in the data set. To verify normal distributions, we compared
QQ-plots against normal distributions for non-logarithmized as well as logarith-
mized glycan data (Supplementary Fig. 10). Since all distributions were closer to
log-normality than to normality, we log-transformed the glycan concentrations
prior to analysis.
Correlation networks and modularity. Correlation networks were computed
using the preprocessed glycan abundances. Regular correlation networks are based
on Pearson product–moment correlation coefﬁcients, which represent the linear
dependency between two variables. However, GGMs are based on partial corre-
lation coefﬁcients, which represent pairwise dependencies in multivariate normally
distributed data when conditioned against all other variables. To obtain a reliable
estimate for the partial correlation matrix, we used the shrinkage-based
GeneNet algorithm31. All partial correlations were corrected for the confounding
effects of age and gender. This is done by including the confounding variables in
the GGM calculation, but not showing them as nodes in the ﬁnal network.
Multiple hypothesis testing was corrected for by controlling the FDR at 0.01
using the Benjamini–Hochberg method32. All partial correlation coefﬁcients
between glycans that had non-signiﬁcant Pearson correlation coefﬁcients were
omitted33. The ﬁnal GGM is represented by all the signiﬁcant partial correlation
coefﬁcients.
The network modularity algorithm was adapted from the widely used
community detection clustering method of Newman34, which optimizes a
modularity Q to determine clusters. In this paper, we used the Q measure to assess
the modularity of predeﬁned clusters, given by the three IgG subclasses. To this
end, subclass-based network modularity was calculated as the relative out-degree
from each subclass to all other subclasses for all signiﬁcantly positive edges. To
assess the signiﬁcance of the observed modularity, we performed graph
randomization via edge rewiring35,36. In this process, two edges in the original
data-driven network are randomly selected and the end nodes of each edge are
swapped. The operation was repeated 10 times the number of edges to reach
sufﬁcient randomization. The entire randomization was repeated 105 times to
obtain a sufﬁcient number of null model networks.
Computations were performed using Matlab R2014a and R 3.1.1.
Pathway analysis. Evidence on substrate speciﬁcities of the four enzymes involved
in IgG glycosylation was based on in vitro experiments17,37–48. For more details,
Supplementary Fig. 1 describes the primary literature for each enzymatic reaction
in Fig. 2.
The pathway analysis and inference were performed using Fisher’s exact tests,
which evaluate whether two categorical variables are statistically independent49,50,
with low P-values indicating a lack of independence. For the purposes of this
analysis, we tested whether signiﬁcant partial correlation coefﬁcients accumulated
at given pathway distances.
Bootstrapping. To statistically compare alternative pathway models, we used
bootstrapping to estimate 95% conﬁdence intervals for the P-values calculated
using Fisher’s exact tests. To do this, we randomly resampled the original cohort to
obtain a new data set with the same number of samples as the original. We then
repeated the entire analysis pipeline, including the GGM calculation and pathway
analysis, and obtained a new Fisher’s P-value for each combination of pathway
rules. Conﬁdence intervals were based on 10,000 resampled data sets.
Genome-wide association study. Genotyping was performed using the Affyme-
trix GeneChip array 6.0 with prephasing by SHAPEIT v2 and imputation by
IMPUTE v2.3.0, using 1000 Genomes (phase 1 integrated haplotypes CEU) as a
reference panel. We limited our analysis to non-monomorphic SNPs that had a
minor allele frequency >1%, a high genotyping quality (call rate >97%), and did
not signiﬁcantly deviate from the Hardy–Weinberg equilibrium (pHWE ≥5 × 106).
Samples with mismatched phenotypic and genetic genders were excluded, leaving
1641 samples and 18,185,628 SNPs to be analyzed. All individuals were of Eur-
opean ancestry.
The glycan measurements were preprocessed using a similar pipeline as that for
the Croatian data in the pathway analysis (see above). Samples from each IgG
subclass were log-transformed and batch-corrected using the ComBat algorithm of
the R package “sva” (R package version 3.14.0). The data were exponentiated to
retrieve the original scale and then normalized using the probabilistic quotient
algorithm30. Glycan ratios were calculated as the product–substrate ratios of all
possible reactions in the IgG glycosylation pathway, as shown in Fig. 5a, and then
log-transformed and regressed against age and sex. A rank-based inverse normal
transformation was applied to the residuals.
For the purposes of this study, we only focused on SNPs located in the regions
of the known glycosylation enzymes—ST6GAL1 (chr.3), B4GALT1 (chr.9), FUT8
(chr.14), and MGAT3 (chr.22)—and with a linkage disequilibrium (LD) and R2≥
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0.8 (Supplementary Table 1). Genomic positions were retrieved from the UCSC
Genomic Browser (GRCh37/hg19)51, while LD information was obtained using the
software SNIPA52.
GWAS was performed with snptest software v2.5.153 using an additive genetic
model. We used an established GWAS signiﬁcance threshold54 corrected for the
number of considered ratios, i.e., 5 ´ 10
8
95 ¼ 5:26 ´ 1010. For suggestive hits, we used
a relaxed threshold of 10−7, as also suggested in ref. 54.
P-gains were introduced to describe the increase in strength of the association
of a ratio compared to the corresponding single glycans. We assume that a
signiﬁcant P-value combined with a high p-gain indicates that the two glycans are
functionally linked in a biochemical reaction involving the gene of the associating
SNP. P-gains were deﬁned as the ratio between the minimum of the association P-
values of single glycans and the association P-value of the corresponding ratio15,18.
The gain in the P-value of the ratio was considered to be signiﬁcant if it was greater
than or equal to 10, as this value indicates gains of one order of magnitude.
This threshold was taken as suggestive also in previous studies, e.g., in Suhre16 and
Shin14. See Supplementary Data 3 for a full list of results.
Validation of inferred reactions in vitro. Substrate preparation: In-house pre-
pared 2-aminobenzamide (2-AB)-labeled IgG glycans55 were pooled and dried in a
vacuum centrifuge to obtain the necessary amount for glycosyltransferase experi-
ments. The preparation of G0-glycopeptide (G0-SGP) and G2-glycopeptide (G2-
SGP) substrates from egg yolk sialylglycopeptide is reported in the Supplementary
Methods. For details about the synthetic substrate preparation, see Supplementary
Methods.
Glycosyltransferase experiments: Expression constructs were generated encoding
the catalytic domains of human B4GALT1 (Uniprot P15291, residues 63–398) and
human MGAT3 (Uniprot Q09327, residues 24–533) as an NH2-terminal fusion
protein in the pGEn2 mammalian expression vector56. Enzymes were expressed in
HEK293-F cells (FreeStyleTM 293-F cells, Thermo Fisher Scientiﬁc, Waltham, MA)
and the secreted protein was puriﬁed by Ni2+-NTA (Qiagen, Valencia, CA) afﬁnity
chromatography by binding, and washing with a column buffer comprising 20 mM
HEPES, 300 mM NaCl, 20 mM imidazole, pH 7.2 and eluted in the same column
buffer containing 300 mM imidazole61. The sample was concentrated and loaded
on a Superdex 75 gel ﬁltration column (GE Healthcare) containing 20 mM HEPES,
200 mM NaCl, 60 mM imidazole, pH 7.2. The eluted GFP fusion proteins were
concentrated to 1 mg/ml and used directly in enzymatic glycan modiﬁcations.
Enzyme activity assays were performed using the UDP-Glo assay (Promega).
B4GALT1 assays were performed using 100 ng of enzyme, 1 mM acceptor (GlcNAc
or G0-SGP), and 1 mM UDP-Gal. The MGAT3 assay was performed using 100 ng
of enzyme, 1 mM acceptor (G0-SGP or G2-SGP), and 1 mM UDP-GlcNAc. The
assay buffer for both enzyme assays contained 100 mM HEPES (pH 7.0), 2 mM
MnCl2, 1 mg/ml BSA in a 10 μL reaction volume at 37 °C for 1 h. Reactions were
stopped by mixing with an equal volume of UDP Detection Reagent (5 μL) and
incubated for 60 min at room temperature. After incubation, luminescence
measurements were performed using a GloMax Multi Detection System plate
reader (Promega). Luminescence values were compared to a standard curve for
quantiﬁcation of UDP produced. Results were also conﬁrmed using mass
spectrometry of the enzymatic products using ESI-MS on a Shimadzu ESI-IT-TOF
instrument.
Analysis of IgG 2-AB glycans after glycosyltransferase experiments: After the
glycosyltransferase experiments, the reaction mixtures (10 μL) were puriﬁed
using AcroPrep Advance 96-well ﬁlter plate, Omega 10K MWCO (Pall) using
vacuum manifold (Pall) at maximum ﬂow rate. The ﬁlter plate was washed twice
with 100 μL of ultrapure water. After adding 50 μL of ultrapure water, each sample
was resuspended, transferred to the ﬁlter plate and the eluate was collected in a
clean PCR plate. This step was repeated twice. The ﬁlter plate was washed with
additional 50 μL of ultrapure water and collected to the same PCR plate (total
volume of 160 μL).
Sample preparation for the HILIC-UPLC analysis: Puriﬁed IgG 2-AB glycans
modiﬁed with glycosyltransferases were analyzed by UPLC based on hydrophilic
interactions (HILIC). Samples were prepared for the analysis by pipetting 20 μL of
each sample and adding 80 μL of cold (4 °C) acetonitrile. Prepared samples were
ﬁltered through AcroPrep Advance 96-well ﬁlter plate, Omega 10K MWCO that
was prewashed twice with 100 μL of ultrapure water using vacuum manifold at
maximum ﬂow rate. Samples (100 μL) were transferred to vials and 40 μL of each
sample was injected to a column. IgG 2-AB glycans were analyzed on a Waters
UPLC as described in the Supplementary Methods. Raw spectral data were then
normalized using the probabilistic quotient method30.
Determination of enzyme colocalization in cell lines. CaCo-2 (https://www.
dsmz.de/catalogues/details/culture/ACC-169.html?tx_dsmzresources_pi5%
5BreturnPid%5D=192) and COS-7 (https://www.dsmz.de/catalogues/details/
culture/ACC-60.html?tx_dsmzresources_pi5%BreturnPid%5D=192) cells (n = 5
each) were grown in DMEM/10% FCS and transfected with the plasmids encoding
the full-length B4GalT1, ST6Gal1, and MGAT3 tagged with either C-terminal
mVenus or mCherry variant57. Transfections were carried out using Lipofectamine
3000 (Invitrogen, Thermo Fisher Scientiﬁc, Carlsbad, CA, USA), according to
manufacturer’s instructions, except that only 500 ng of the plasmids cDNAs were
used for the transfections and the cells were ﬁxed for immunoﬂuorescence
microscopy already after 1 day. These procedures helped to keep the expression
levels sufﬁciently low to avoid disturbing normal localization of the proteins in the
Golgi. After ﬁxation (4% paraformaldehyde/PBS, 20 min), blocking and permea-
bilization (1% BSA, 0.1% saponin in PBS, pH 7.4) the cells were co-stained with the
cis-Golgi marker antibody (monoclonal anti-GM130, Thermo Scientiﬁc, Cheshire,
UK, 1:250 dilution, https://www.ﬁshersci.com/shop/products/anti-gm130-clone-
35-bd-2/bdb610822#?keyword=610822) together with Alexa Fluor 594-conjugated
goat anti-mouse secondary antibodies (Molecular Probes, Eugene, OR, USA, 1:500
dilution, https://www.thermoﬁsher.com/antibody/product/Goat-anti-Mouse-IgG-
H-L-Cross-Adsorbed-Secondary-Antibody-Polyclonal/A-11020). After staining,
cells were embedded with Immu-Mount (Thermo Scientiﬁc, Cheshire, UK) and
stained specimens were examined and photographed using the Zeiss LSM710
confocal microscope with 100× oil immersion objective (n.a.= 1.3). 30–40 sections
at 0.3 µm intervals were taken from the selected regions using the pinhole setting to
1. The signal intensities in each channel were quantiﬁed from each Z-stack image
using the image quantiﬁcation module of the Zen 2009 software. The same soft-
ware package was used to calculate the overall colocalization of each enzyme pair
or enzyme–Golgi marker pair. The values are expressed as overlap coefﬁcient
percentages (mean %± standard deviation) obtained using pixel per pixel com-
parison of each Z-stack image and by averaging the values for each set of Z-stack
images. The presented values therefore illustrate the overall colocalization of the
proteins throughout each Golgi structure examined.
Data availability. The informed consent given by KORA study participants does
not cover data posting in public databases. However, data are available upon
request from KORA-gen (http://epi.helmholtz-muenchen.de/kora-gen). Requests
are submitted online and are subject to approval by the KORA board. Preprocessed
glycan concentrations, as well as values corrected for age and gender, are available
in the ﬁgshare repository with the identiﬁer doi:10.6084/m9.ﬁgshare.5335861.
Note that for conﬁdentiality reasons, age and gender data cannot be shared
publicly, and we therefore additionally provide the corrected glycan values. A GGM
inferred on this corrected data matrix will be largely identical to the one presented
in this paper.
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